1.       Adel Fahmideh M, Scheurer ME. Pediatric Brain Tumors: Descriptive Epidemiology, Risk Factors, and Future Directions. Cancer Epidemiol Biomarkers Prev. 2021 May;30(5):813-821. doi: 10.1158/1055-9965.EPI-20-1443. Epub 2021 Mar 2. PMID: 33653816.

2.       Becker AP, Scapulatempo-Neto C, Carloni AC, et al. KIAA1549: BRAF gene fusion and FGFR1 hotspot mutations are prognostic factors in pilocytic astrocytomas. J Neuropathol Exp Neurol 2015;74: 743-54.

3.       Cheng Sylvia and Singhal, A. and B. U. Central Nervous System Germ Cell Tumors (CNS GCTs). In E. Scheinemann Katrin and Bouffet (Ed.), Pediatric Neuro-oncology 2024 (pp. 259–275). Springer International Publishing. https://doi.org/10.1007/978-3-031-62017-1_15

4.       Cohen AR. Brain Tumors in Children. N Engl J Med. 2022 May 19;386(20):1922-1931. doi: 10.1056/NEJMra2116344. PMID: 35584157.

5.       Collins KL, Pollack IF. Pediatric Low-Grade Gliomas. Cancers (Basel). 2020 May 4;12(5):1152. doi: 10.3390/cancers12051152. PMID: 32375301; PMCID: PMC7281318.

6.       Crotty EE, Sato AA, Abdelbaki MS. Integrating MAPK pathway inhibition into standard-of-care therapy for pediatric low-grade glioma. Front Oncol. 2025 Feb 11;15:1520316. doi: 10.3389/fonc.2025.1520316. PMID: 40007996; PMCID: PMC11850343.

7.       Dalmage, M., LoPresti, M. A., Sarkar, P., et al Survival and neurological outcomes after stereotactic biopsy of diffuse intrinsic pontine glioma: a systematic review. In Journal of Neurosurgery: Pediatrics 2023;32 (6):665–672.

8.       Ellison DW, Aldape KD, Capper D, et al. cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors. Brain Pathol 2020;30:863-6.

9.       Gajjar, A., Mahajan, A., Bale, T., et al. Pediatric Central Nervous System Cancers, Version 2.2025. JNCCN Journal of the National Comprehensive Cancer Network, 2025;23(3):113–130

10.   Johnson KJ, Cullen J, Barnholtz-Sloan JS, et al. Childhood brain tumor epidemiology: a brain tumor epidemiology consortium review. Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2716-36. doi: 10.1158/1055-9965.EPI-14-0207. Epub 2014 Sep 5. PMID: 25192704; PMCID: PMC4257885.

11.   Jones DT, Kocialkowski S, Liu L, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 2008;68:8673-7

12.   Juraschka K, Taylor MD. Medulloblastoma in the age of molecular subgroups: a review. J Neurosurg Pediatr 2019;24: 353-63.

13.   Kallappagoudar S, Yadav RK, Lowe BR, et al. Histone H3 mutations — a special role for H3.3 in tumorigenesis? Chromosoma 2015;124:177-89.

14.   Kebudi, R., Cakir, F. B., Bay, S. B, et al. Nimotuzumab-containing regimen for pediatric diffuse intrinsic pontine gliomas: a retrospective multicenter study and review of the literature. Child’s Nervous System, 2019;35(1), 83–89.

15.   Khan Sara and Ramaswamy, V.. Medulloblastoma. In E. Scheinemann Katrin and Bouffet (Ed.), Pediatric Neuro-oncology 2024;pp. 203–219. Springer International Publishing. https://doi.org/10.1007/978-3-031-62017-1_12

16.   Korshunov A, Schrimpf D, Ryzhova M, et al. H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers. Acta Neuropathol 2017;134:507-16.

17.   Kumar, R., Smith, K. S., Deng, M.,. Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. J Clin Oncol, 2021;39, 807–821.

18.   Kutluk T, Ahmed F, Cemaloğlu M,. Progress in palliative care for cancer in Turkey: a review of the literature. Ecancermedicalscience. 2021;Nov 25;15:1321. doi: 10.3332/ecancer.2021.1321. PMID: 35047072; PMCID: PMC8723752.

19.   Lim-Fat, M. J., Bennett, J., Ostrom, Q., Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology Consensus Review on diagnosis, management, and future directions. Neuro-Oncology, 2025;27(1), 13–32.

20.   Lu VM, Elarjani T, Niazi TN. Global, Regional, and National Incidence and Mortality Trends in Pediatric Central Nervous System Tumors over the Past 2 Decades. World Neurosurg. 2023 Nov;179:e568-e574. doi: 10.1016/j.wneu.2023.09.003. Epub 2023 Sep 7. PMID: 37683927.

21.   Malbari F, Lindsay H. Genetics of common pediatric brain tumors. Pediatr Neurol 2020;104:3-12.

22.   Marinoff AE, Ma C, Guo D, et al. Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival. J Neurooncol 2017;135:201-11.

23.   McKean-Cowdin R, Razavi P, Barrington-Trimis J, et al. Trends in childhood brain tumor incidence, 1973–2009. J Neurooncol 2013;115:153-60.

24.   Merchant TE, Bendel AE, Sabin ND, Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma. J Clin Oncol. 2019 Apr 20;37(12):974-983. doi: 10.1200/JCO.18.01765. Epub 2019 Feb 27. PMID: 30811284; PMCID: PMC7186586.

25.   Mosaab A, El-Ayadi M, Khorshed EN, et al. Histone H3K27M mutation overrides histological grading in pediatric gliomas. Sci Rep 2020;10:8368.

26.   Nobre L, Zapotocky M, Khan S, et al. Pattern of relapse and treatment response in WNT-activated medulloblastoma. Cell Rep Med 2020;1:100038.

27.   Ostrom QT, Adel Fahmideh M, Cote DJ, et al. Risk factors for childhood and adult primary brain tumors. Neuro Oncol. 2019 Nov 4;21(11):1357-1375. doi: 10.1093/neuonc/noz123. PMID: 31301133; PMCID: PMC6827837.

28.   Ostrom, Q. T., Price, M., Ryan, K., CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018. Neuro-Oncology, 2022;24, III1–III38.

29.   Packer RJ, Cogen P, Vezina G, Rorke LB. Medulloblastoma: clinical and biologic aspects. Neuro Oncol 1999;1:232-50.

30.   Pajtler KW, Witt H, Sill M, et al. Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell 2015;27:728-43.

31.   Panwalkar P, Clark J, Ramaswamy V, et al. Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group A childhood posterior fossa ependymoma and is a powerful predictor of outcome. Acta Neuropathol 2017;134: 705-14.

32.   Paulino AC, Wen BC, Buatti JM, et al. Intracranial ependymomas: an analysis of prognostic factors and patterns of failure. Am J Clin Oncol 2002;25:117-22.

33.   Plant-Fox AS, O'Halloran K, Goldman S. Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae. Curr Probl Cancer. 2021 Aug;45(4):100777. doi: 10.1016/j.currproblcancer.2021.100777. Epub 2021 Jul 16. PMID: 34303558.

34.   Siegel DA, King JB, Lupo PJ, Counts, incidence rates, and trends of pediatric cancer in the United States, 2003-2019. J Natl Cancer Inst. 2023 Nov 8;115(11):1337-1354. doi: 10.1093/jnci/djad115. PMID: 37433078; PMCID: PMC11018256.

35.   Sturm D, Pfister SM, Jones DTW. Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management. J Clin Oncol. 2017 Jul 20;35(21):2370-2377. doi: 10.1200/JCO.2017.73.0242. Epub 2017 Jun 22. PMID: 28640698.

36.   Udaka, Y. T., & Packer, R. J.. Pediatric Brain Tumors. In Neurologic Clinics. 2018;36(3),533–556. W.B. Saunders. https://doi.org/10.1016/j.ncl.2018.04.009

37.   Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 2014;64:83-103.